One collection. Multiple results. ThinPrep® Pap + Aptima® HPV Together:
Providing a Comprehensive Suite of Cervical Health Testing l Health esting
The ThinPrep® Pap Test The only Pap test with FDA-approved labeling for detection of glandular disease.1-6
ThinPrep® Pap Test
ThinPrep® Imaging System Independent studies show greater LSIL and HSIL categorization and 67% decrease in UNSAT rate versus non-imaged slides.7-10
0 Genesis™ Processor ThinPrep® Review Scope Manual+ ThinPrep® d ThinPrep® Imaging System
Aptima® HPV Assay The only FDA-approved mRNA-based test, shown to reduce false positives by 24%-40% compared to a DNA based test.11,12
f HPV type 45, the third most com type in invasive cervical cancers, identifies
Aptima® HPV 16 18/45 Genotype Assay
Aptima® HPV 16 18/45 Genotype Assay Inclusion of HPV type 45, the third most common HPV type in invasive cervical cancers, identifies women at risk for adenocarcinoma with minimal impact to colposcopy rates.13,14
e Assay n
women at risk for adenocarcinoma with minimal impact to colposcopy rates.13,14
Aptima® HPV Assay
Panther® System
CE - M AR K E D
Powering Healthcare with Technology to S
The G
digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric g t
l c t
imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and c
d p
cervical cancer screening and ushering in a new era of cytology innovation.
d cervical cancer cells in women – transforming l c
f c to
o Shape the Future of Digital Diagnostics e Genius™ Digital Diagnostics System* is the first
*Not available for sale in the USA
References: 1. Schorge JO, et al. ThinPrep detection of cervical and a typical endocervical cells: a retrospective cohort study. Cancer Cytopathol. 2002;96:338-343. 2. Bai H, et al. ThinPrepPap Test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol. 2000;23:19-22. 3. Carpenter AB, et al. ThinPrep Pap Test: Performance biopsy follow-up in a universityhospital. Cancer. 1999;87:105-112. 4. Guidos BJ, et al. Detection of endometrial adenocarcinoma with the ThinPrep Pap Test. Diagn Cytopathol. 2000;23:260-265. 5. Ashfaq R, et al. ThinPrepPap Test: Accuracy for glandular disease. Acta Cytol. 1999;43:81-85. 6. Wang N, et al. Histologic follow-up of atypical endocervical cells. Liquidbased, thin-layer preparation vs. conventional papsmear. Acta Cytol. 2002;46:453-457. 7. Dziura B, et al. Performance of an imaging system vs. manual screening in the detection of squamous intra epithelial lesions of the uterine cervix. Acta Cytol. 2006;50(3):309-11. 8. Lozano R. Comparison of computer-assisted and manual screening of cervical cytology. Gynecol Oncol. 2007;104(1):134-8. 9. Miller FS, et al. Implementation of the ThinPrep imaging system in a high-volume metropolitan laboratory. Diagn Cytopathol. 2007;35(4):213-7. 10. Klug SJ, Neis KJ, Harlfinger W, et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. Int J Cancer. 2013;132(12):2849-2857. 11. Aptima HPV Assay [package insert]. AW-12820. San Diego, CA; Hologic, Inc., 2020. Table #13. 12. Monsonego, J., Hudgens, M.G., Zerat, L., Zerat, J.-C., Syrjänen, K., Halfon, P., Ruiz, F. and Smith, J.S. (2011), Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: The FASE study. Int. J. Cancer. 129: 691-701. doi:10.1002/ ijc.25726 13. de Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056. 14. Hopenhayn C, et al. Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine Introduction. J of Low Genit Tract Dis. 2014;18(3):182-9.
ADS-03098-001 Rev. 002 © 2021 Hologic, Inc. All rights reserved. Hologic, Aptima, ThinPrep, Panther, Pap + HPV Together, Genius and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to
diagnostic.solutions@
hologic.com.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50
